Boehringer Ingelheim and Zai Lab announced a clinical collaboration to evaluate a dual DLL3-targeting combination therapy for small cell lung cancer (SCLC) and neuroendocrine carcinomas. The Phase Ib/II study will test obrixtamig, a DLL3/CD3 T-cell engager, combined with zocilurtatug pelitecan (zoci), a DLL3-targeting ADC. Both drugs have shown e...

The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significan...

Chinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.

Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.

Over 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.